AllianceBernstein (AB)
(Delayed Data from NYSE)
$33.55 USD
+0.23 (0.69%)
Updated May 31, 2024 04:00 PM ET
After-Market: $33.55 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth D Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
AB 33.55 +0.23(0.69%)
Will AB be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for AB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AB
AllianceBernstein's (AB) April AUM Falls on Market Depreciation
AB vs. SEIC: Which Stock Is the Better Value Option?
AB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Are Finance Stocks Lagging Bain Capital Specialty Finance (BCSF) This Year?
Are Investors Undervaluing AllianceBernstein (AB) Right Now?
Why AllianceBernstein (AB) Might Surprise This Earnings Season
Other News for AB
AB Science is providing a summary of the live webcast held on May 30, 2024, giving an update on the application for conditional marketing authorization of masitinib in ALS
AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS
3 Best Dividend Stocks to Buy in May 2024, as per Analysts
HSBC’s new offices are coaxing hybrid workers into the office more frequently
Onur Erzan, Head of Global Client Group and Private Wealth, to Participate in the TD Financial Services & Fintech Summit on June 6th, 2024